Pharmaceutical and healthcare company Abbott Laboratories and the Canadian Association of Radiation Oncology (CARO) have reached a $2 million Canadian ($2 million U.S.) milestone with their partnership of providing prostate cancer research grants.
For the 10th consecutive year, Abbott has underwritten the ACURA Uro-Oncologic Radiation Awards, in which $200,000 Canadian ($200,000 U.S.) is awarded to up to 10 individuals conducting prostate cancer research.
Funds are used for basic science, translational, clinical, and population-based prostate cancer research, according to the organization. Prior recipients, who have included research scientists, medical physicists, and radiation oncologists, used the seed funding to test unique radiation treatment ideas including biomarkers, imaging, brachytherapy, radiosurgery, and radiosensitizers.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
